Skip to search formSkip to main contentSkip to account menu

Transaction counts and value totals - year

Known as: year 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).
511Background: Retrospective data suggest that patients (pts) with small HER2+ cancers have more than just minimal risk of… 
Review
2015
Review
2015
Lipid Profile Changes in the Severely Obese after Laparoscopic Sleeve Gastrectomy (LSG), 1, 3, and 5 Years after Surgery
BackgroundSince there is an increasing acceptance of the laparoscopic sleeve gastrectomy (LSG) and limited information regarding… 
2011
2011
Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
6506 Background: Dasatinib, a potent BCR-ABL inhibitor, is approved for use as 1st- and 2nd-line therapy for CML pts with newly… 
2011
2011
Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial.
4547 Background: Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1-3… 
Highly Cited
2010
Highly Cited
2010
Polyphenol content and antioxidant activity of California almonds depend on cultivar and harvest year.
2008
2008
Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and preoperative MRI
509 Background: Surgical treatment for early stage breast cancer (ca) includes mastectomy (mast) or lumpectomy. The influence of… 
2007
2007
Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group
10005 Background: IM the first-line targeted therapy for advanced GIST, must not be interrupted after one year (yr) in responding… 
Highly Cited
2004
Highly Cited
2004
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.
Rituximab, chimeric anti-human CD20 monoclonal antibody approved for B-cell lymphoma, depletes circulating B cells. Little data… 
1999
1999
Telomere shortening with aging in human esophageal mucosa
Progressive telomere shortening with aging was studied using normal esophageal mucosal specimens from 177 human subjects aged… 
1994
1994
Prognostic value of MDR1 gene expression in neuroblastoma: results of a multivariate analysis.
The prognostic value of the MDR1 gene expression in neuroblastoma (NB) was assessed in a multivariate analysis performed in a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)